Vivonics, Inc. SBIR Phase I Award,

The goal of this NIH Phase I SBIR proposal is to develop and validate a new method to monitor the symptomatic toxicities and health related quality of life of cancer patients who are undergoing and have undergone radiation therapy during the course of their treatmentThe proposal is built around expertise in mobile application developmentVivonics Incand radiation oncologyDrTJ Fitzgerald of the University of Massachusetts Medical SchoolPhase I will allow this uniquely qualified team to developtestand validate the proposed mobile application that we call Symptomatic Toxicity Mobile MonitorSympTMMImprovements to both the quality and availability of cancer treatment has led to a marked increase in the number of patients surviving canceroften times for a previously unimaginable number of yearsInof patients survived greater thanyearsgreater thanandgreater thanafter diagnosisDe MoorMariotto et alThe caveat is that while survivors are living longerthe volume of new cancer patients each year is steadily increasingThis trend is expected to continue over the coming decadetaxing our limited understanding of the longer term impacts on the various treatments used today